HEALTHCARE RESOURCE UTILIZATION AND COSTS AMONG OVERACTIVE BLADDER PATIENTS WITH AND WITHOUT URINARY INCONTINENCE: A U.S. CLAIMS-BASED ANALYSIS
Author(s)
Vikash Kumar Verma, MBA, PharmD1, Louis Brooks Jr, MS2, Marissa Seligman, PharmD3, Abhimanyu Roy, MBA4, Abhinav Nayyar, MBA, MBBS5, Ankitkumar Arora, MPharm6, Anuj Gupta, Msc7, Vishan Khatavkar, MBA8, Ram Kumar Mishra, PhD9, Kirti Kirti, MS, PharmD10, Sushil Kumar Singh, Other11, Piyush kumar, MPH12, Anshika Singh, BTech13, Arunima Sachdev, MA4, Satish Kumar, MBA8.
1Optum Lifesciences, Boston, MA, USA, 2Optum, Bloomsbury, NJ, USA, 3Optum, Winchester, MA, USA, 4Optum, Gurgaon, India, 5Optum Life Sciences, Gurugram, India, 6Optum Global Solutions, Gurgaon, India, 7Optum Life Sciences, Noida, India, 8Optum Lifesciences, Gurugram, India, 9Optum Global Solution, Gurugram, India, 10optum, Noida, India, 11Optum Global Solutions, Gurugram, India, 12Student, Dehradun, India, 13Optum Lifesciences, Noida, India.
1Optum Lifesciences, Boston, MA, USA, 2Optum, Bloomsbury, NJ, USA, 3Optum, Winchester, MA, USA, 4Optum, Gurgaon, India, 5Optum Life Sciences, Gurugram, India, 6Optum Global Solutions, Gurgaon, India, 7Optum Life Sciences, Noida, India, 8Optum Lifesciences, Gurugram, India, 9Optum Global Solution, Gurugram, India, 10optum, Noida, India, 11Optum Global Solutions, Gurugram, India, 12Student, Dehradun, India, 13Optum Lifesciences, Noida, India.
OBJECTIVES: Overactive bladder (OAB) is a chronic condition characterized by urinary urgency, frequency, and nocturia, often accompanied by urinary incontinence (UI), which can significantly impact quality of life and healthcare costs. This study quantified healthcare resource utilization (HCRU) and costs among patients with urgency UI (UUI), stress UI (SUI), or mixed UI (MUI) in the context of OAB and assessed demographic and economic disparities to inform targeted interventions.
METHODS: A retrospective cohort study using Optum® Market Clarity claims data (January 2018-June 2023) identified adults (≥18 years) with OAB via ICD-10 codes. Two cohorts were defined: OAB with subsequent UI within 1 year (cases); and OAB only (controls). The index date was the first OAB diagnosis within the index period; for cases, UI occurred after OAB; for controls. Continuous enrollment for 12 months pre- and 24 months post-index was required. Patients with diuretic use, neuropathic bladder, or pregnancy were excluded. Propensity score matching (1:1) balanced the demographics and comorbidity burden (Charlson Comorbidity Index [CCI]).
RESULTS: After matching, 148,931 patients were included in each group. A majority were female (39.3%), aged ≥65 years, Caucasian (35.8%), and from the Midwest (12.6%); most had a CCI score of 1-2 (22.5%). Over 24 months, cases had higher ambulatory [41.41 (34.92) vs. 36.56 (32.44)] and office utilization [30.31 (29.41) vs. 26.25 (26.83)], but lower inpatient use [2.26 (8.38) vs. 2.74 (9.44)] than controls (p < 0.0001 for all HCRU comparisons). Costs followed similar trends: ambulatory [$24,866.23 ($31,860.38) vs. $22,715.34 ($32,277.98)], office [$7,731.56 ($11,156.49) vs. $6,671.19 ($10,916.73)], and inpatient [$27,226.32 ($75,659.31) vs. $33,899.60 ($92,592.37)] (p < 0.0001 for all cost comparisons).
CONCLUSIONS: OAB patients with UI incur higher healthcare costs and utilization (ambulatory and office), except for inpatient cost. These variations emphasize the need for targeted interventions to reduce economic burden and improve outcomes.
METHODS: A retrospective cohort study using Optum® Market Clarity claims data (January 2018-June 2023) identified adults (≥18 years) with OAB via ICD-10 codes. Two cohorts were defined: OAB with subsequent UI within 1 year (cases); and OAB only (controls). The index date was the first OAB diagnosis within the index period; for cases, UI occurred after OAB; for controls. Continuous enrollment for 12 months pre- and 24 months post-index was required. Patients with diuretic use, neuropathic bladder, or pregnancy were excluded. Propensity score matching (1:1) balanced the demographics and comorbidity burden (Charlson Comorbidity Index [CCI]).
RESULTS: After matching, 148,931 patients were included in each group. A majority were female (39.3%), aged ≥65 years, Caucasian (35.8%), and from the Midwest (12.6%); most had a CCI score of 1-2 (22.5%). Over 24 months, cases had higher ambulatory [41.41 (34.92) vs. 36.56 (32.44)] and office utilization [30.31 (29.41) vs. 26.25 (26.83)], but lower inpatient use [2.26 (8.38) vs. 2.74 (9.44)] than controls (p < 0.0001 for all HCRU comparisons). Costs followed similar trends: ambulatory [$24,866.23 ($31,860.38) vs. $22,715.34 ($32,277.98)], office [$7,731.56 ($11,156.49) vs. $6,671.19 ($10,916.73)], and inpatient [$27,226.32 ($75,659.31) vs. $33,899.60 ($92,592.37)] (p < 0.0001 for all cost comparisons).
CONCLUSIONS: OAB patients with UI incur higher healthcare costs and utilization (ambulatory and office), except for inpatient cost. These variations emphasize the need for targeted interventions to reduce economic burden and improve outcomes.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE189
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Urinary/Kidney Disorders